McCord Research, Inc., a research company supporting better health through science, was recently granted a second US patent (US Patent No. 8,796,315). This patent describes a method for accelerating wound closure to improve wound healing.  

According to the inventor, Dr McCord, this method includes administering or transplanting to individuals who require wound healing, a composition of an effective amount of hydroxytyrosol and oleuropein and cells derived from umbilical cord blood, such that the administration of the combination reduces the time required for wound healing by at least approximately 30% in comparison to treatment with just cells derived from umbilical cord blood alone.

Endothelial cells form the inner lining of a blood vessel and provides an anticoagulant barrier between the vessel wall and blood. Endothelial cells have a vital role in wound repair especially for patients with vascular disease and diabetes.  The restoration of these cells allows for vital nutrients to be delivered to the skin and wound through the small network of capillaries that form at the dermal epidermal junction. The endothelial cells additionally regulate hemostasis, vasomotor tone, angiogenesis and vasculogenesis and immune and inflammatory responses. In addition, the endothelial cell plays a pivotal role in wound care. "Endothelial cell injury is the genesis of many pathologic states including atherosclerosis, loss of semi-permeable membrane function, and thrombosis. Restoring the viability of endothelial cells has far reaching health implications," stated Dr McCord.

McCord Research is seeking worldwide patent protection for its wound care technology and looks forward to healing wounds on a global basis. The technology is currently being licensed under the Olivamine 10 brand name in the United States and Asia for the treatment of wounds in humans and animals.